Literature DB >> 10421055

Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7- T lymphocyte subsets in Sézary syndrome.

R Dummer1, F O Nestle, E Niederer, E Ludwig, E Laine, H Grundmann, P Grob, G Burg.   

Abstract

The expansion of CD4+CD7- T cells in the peripheral blood of Sézary syndrome (SS) is well known. It remains unclear whether this population contains the dominant T cell clone. Peripheral blood mononuclear cells (PBMC) of five SS patients were sorted by fluorescence-activated cell sorting into CD4+CD7- and CD4+CD7+ populations. These populations were analysed separately for clonality of the T cell receptor gamma chain (TCR-gamma) by PCR-DGGE. The cytokine profile of both populations was investigated by RT-PCR ELISA for IFN-gamma, IL-2, IL-4, IL-5, IL-10, IL-13 and IL-15. In three other patients with known Vbeta-usage, the dominant T cell clones were phenotypically characterized by double staining. PCR-DGGE of TCR-gamma demonstrated that all patients had a clonal population in their blood and that this population was present in CD4+CD7- and CD4+CD7+ populations. Concerning mRNA cytokine transcription, the two populations did not show any consistent differences. In three patients with identified clones (Vbeta 3.1, 5.3 and 6.7), double staining revealed positivity for CD2, CD3, CD4, CD5, CD45RO and CD7 in a significant proportion (at least 35%). We conclude that the CD4+CD7- population does not represent the dominant T cell clone in patients with SS. An increase in this population of PBMC in SS might account for deviations in the T cell functions of the patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421055     DOI: 10.1007/s004030050414

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  6 in total

Review 1.  T cell signal transduction and the role of CD7 in costimulation.

Authors:  R Stillwell; B E Bierer
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Sézary Syndrome: Clinical and Biological Aspects.

Authors:  Rebecca Kohnken; Stephanie Fabbro; Justin Hastings; Pierluigi Porcu; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

3.  Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Authors:  Elise A Olsen; Sean Whittaker; Youn H Kim; Madeleine Duvic; H Miles Prince; Stuart R Lessin; Gary S Wood; Rein Willemze; Marie-France Demierre; Nicola Pimpinelli; Maria Grazia Bernengo; Pablo L Ortiz-Romero; Martine Bagot; Teresa Estrach; Joan Guitart; Robert Knobler; José Antonio Sanches; Keiji Iwatsuki; Makoto Sugaya; Reinhard Dummer; Mark Pittelkow; Richard Hoppe; Sareeta Parker; Larisa Geskin; Lauren Pinter-Brown; Michael Girardi; Günter Burg; Annamari Ranki; Maartan Vermeer; Steven Horwitz; Peter Heald; Steve Rosen; Lorenzo Cerroni; Brigette Dreno; Eric C Vonderheid
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

4.  Novel approach to gene expression profiling in Sézary syndrome.

Authors:  R G Pomerantz; E D Mirvish; G Erdos; L D Falo; L J Geskin
Journal:  Br J Dermatol       Date:  2010-11       Impact factor: 9.302

5.  Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.

Authors:  K Fujii; M B Karpova; K Asagoe; O Georgiev; R Dummer; M Urosevic-Maiwald
Journal:  Leukemia       Date:  2015-04-27       Impact factor: 11.528

6.  A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy.

Authors:  LaBaron T Washington; Yang O Huh; Linda C Powers; Madeleine Duvic; Dan Jones
Journal:  BMC Clin Pathol       Date:  2002-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.